• LAST PRICE
    5.0500
  • TODAY'S CHANGE (%)
    Trending Up0.0600 (1.2024%)
  • Bid / Lots
    5.0000/ 6
  • Ask / Lots
    5.0500/ 2
  • Open / Previous Close
    4.9900 / 4.9900
  • Day Range
    Low 4.9300
    High 5.1200
  • 52 Week Range
    Low 2.6800
    High 7.2800
  • Volume
    439,637
    average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 4.99
TimeVolumeCAPR
09:32 ET488155.0016
09:34 ET161874.99
09:41 ET11004.998
09:43 ET23995.005
09:52 ET3004.99
09:54 ET21025
09:56 ET22655
09:57 ET2005.02
09:59 ET64475.0511
10:01 ET20505.07
10:03 ET49475.055
10:08 ET3005.025
10:10 ET1005.0144
10:12 ET39374.99
10:14 ET3005.03
10:17 ET16655.04
10:19 ET133625.09
10:21 ET32695.07
10:28 ET12825.06
10:30 ET1005.0501
10:35 ET7215.07
10:37 ET8005.04
10:39 ET2005.05
10:44 ET29995.06
10:46 ET1005.04
10:48 ET6005.01
10:51 ET3195.02
10:53 ET30005.0201
10:57 ET1005.01
11:00 ET102005.025
11:08 ET2215.03
11:09 ET4635.02
11:11 ET1005
11:13 ET64355.0067
11:15 ET5005.01
11:18 ET2005.01
11:20 ET15505
11:26 ET9695
11:27 ET1004.995
11:29 ET1324.997
11:31 ET29684.98
11:33 ET8974.958
11:36 ET13004.95
11:38 ET7084.97
11:40 ET47285
11:42 ET10085.01
11:44 ET1995
11:45 ET10005.016
11:47 ET14004.98
11:49 ET14004.9701
11:58 ET6114.99
12:00 ET1084.9875
12:02 ET26004.97
12:03 ET12724.96
12:05 ET6004.97
12:09 ET3004.98
12:12 ET5844.99
12:14 ET11004.98
12:16 ET28224.97
12:18 ET11284.98
12:30 ET1004.96
12:32 ET9004.96
12:34 ET31004.955
12:36 ET7124.95
12:38 ET1004.94
12:39 ET1004.93
12:43 ET12004.96
12:48 ET2004.95
12:50 ET1504.9598
12:57 ET28324.99
12:59 ET20004.9701
01:03 ET10004.96
01:10 ET41004.99
01:12 ET3004.98
01:14 ET74504.99
01:17 ET12005
01:19 ET1004.99
01:24 ET4284.98
01:30 ET6544.96
01:44 ET2004.97
01:48 ET1784.97
01:57 ET1004.98
02:13 ET2004.99
02:15 ET6004.99
02:22 ET21864.995
02:24 ET1004.995
02:26 ET1005
02:27 ET3005.0099
02:36 ET3005.0284
02:42 ET2005.02
02:44 ET1005.035
02:45 ET3005.035
02:47 ET3005.0301
02:49 ET1005.036
02:51 ET5005.03
02:54 ET17585.03
02:58 ET4005.04
03:00 ET5005.03
03:05 ET4295.03
03:09 ET10005.03
03:12 ET1005.03
03:16 ET9455.0286
03:18 ET4085.03
03:20 ET3005.03
03:21 ET1005.03
03:23 ET2005.04
03:25 ET9005.0463
03:27 ET6015.0411
03:30 ET2005.045
03:32 ET13395.055
03:34 ET6745.06
03:36 ET6675.075
03:38 ET13505.056
03:39 ET15005.055
03:41 ET3005.04
03:45 ET20725.0201
03:48 ET4005.02
03:50 ET37235.015
03:52 ET304485.0399
03:54 ET15325.06
03:56 ET23965.055
03:57 ET22765.04
03:59 ET1022745.05
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCAPR
Capricor Therapeutics Inc
164.3M
-5.4x
---
United StatesCLLS
Cellectis SA
158.4M
-1.2x
---
United StatesELUT
Elutia Inc
136.2M
-1.3x
---
United StatesFENC
Fennec Pharmaceuticals Inc
143.4M
134.7x
---
United StatesCGEN
Compugen Ltd
163.9M
-17.2x
---
United StatesMDWD
Mediwound Ltd
189.6M
-8.1x
---
As of 2024-09-21

Company Information

Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. The Company leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases.

Contact Information

Headquarters
10865 Road to the Cure, Suite 150SAN DIEGO, CA, United States 92121
Phone
858-727-1755
Fax
302-655-5049

Executives

Executive Chairman of the Board
Frank Litvack
President, Chief Executive Officer, Director
Linda Marban
Chief Financial Officer
Anthony Bergmann
Executive Vice President, General Counsel
Karen Krasney
Independent Director
Paul Auwaerter

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$164.3M
Revenue (TTM)
$27.2M
Shares Outstanding
32.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
3.92
EPS
$-0.93
Book Value
$0.73
P/E Ratio
-5.4x
Price/Sales (TTM)
6.1
Price/Cash Flow (TTM)
---
Operating Margin
-110.50%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.